“If you’re doing it for weight loss, sometimes they’re not covered by insurance. So it can be a little bit cheaper to get it compounded,” said Abby Beadle, a pharmacist at Hometown Pharmacy.
Rising costs for brand-name medications like Ozempic and Wegovy are driving patients toward compounded alternatives. Unlike FDA-regulated drugs, these custom-made mixtures bypass the standard federal review process before reaching consumers.
Health officials warn that patients purchasing these unapproved alternatives often lack clarity regarding active ingredients and proper dosing. Regulatory bodies continue to monitor compounding facilities amid ongoing supply adjustments.
Federal Regulators Increase Pressure on Telehealth Weight-Loss Drug Ads
Federal regulators have increased pressure on telehealth firms advertising custom weight-loss drugs.
Recent enforcement actions include 30 letters announced in March and 25 announced in June. Agencies cited companies for suggesting compounded drugs match brand-name medicines like Wegovy and Zepbound.
“They don’t know what the actual formulation is and what the dose is, I would say not recommended. Not advised,” said Dr. Ian Neeland, a cardiologist at University Hospitals.
State enforcement mirrors federal scrutiny. Cameron McNamee, director of policy and communications for the State Board of Pharmacy, noted that Ohio regulations align with federal standards requiring patient-specific prescriptions.
“We have been taking a lot of administrative actions against these pharmacies,” McNamee said, adding that the board inspects compounding facilities annually.
Millions May Lose Access If GLP-1 Compounding Stops
OpenLoop Health chief medical officer Dr. Mohit Joshipura estimated that at least 6 million Americans would lose access to their medications if compounding stopped.
Compounding copies of GLP-1 drugs was generally permitted during a shortage that began in 2022. Restrictions returned in late 2024 and early 2025 as brand-name supplies recovered.
State officials recommend verifying pharmacy licenses before purchasing treatments. Patients can report concerns directly to regulatory authorities.
Patient Questions About Compounded GLP-1s
Are compounded GLP-1 drugs approved by federal regulators?
No. The FDA does not review compounded drugs for safety, effectiveness, or quality before they are sold, according to Medical Daily.
How long do companies have to answer federal warning letters?
Firms receiving FDA warning letters are asked to respond in writing within 15 business days, Medical Daily reported.
Dr. Ian Neeland, a cardiologist at University Hospitals, directs cardiovascular prevention and co-directs the Center for Integrated and Novel Approaches in Vascular-Metabolic Disease at the Harrington Heart and Vascular Institute.
He earned his medical degree from the Icahn School of Medicine at Mount Sinai in 2007, completed internal medicine residency and a chief resident year at Emory University Hospital, and finished a combined clinical and research fellowship in cardiovascular medicine at UT Southwestern Medical Center in Dallas. He holds the McCamon Family Chair in Cardiovascular Excellence and is an associate professor at Case Western Reserve University School of Medicine.
What should patients check before purchasing medication?
Patients should ask which pharmacy made the product, whether that facility is licensed in their state, and whether a valid prescription is required, as outlined by Medical Daily.
Worth a look